News & Insights
All the latest News and Insights from OHE, plus an archive of our monthly email bulletin.
Latest Insights
OHE’s submission to a parliamentary inquiry on UK drug shortages
The following is an extract from OHE’s written submission to parliament focused on diversifying suppliers and recognising the value of treatment alternatives to mitigate this issue.
Environmental sustainability in the NHS 10 Year Health Plan: The need for green
This is the second in a series of blogs about how the proposals in the recently published 10 Year Plan measure up against some of the most pressing health concerns in the UK.
Around the World in HTAs: Saudi Arabia – Navigating the healthcare and HTA landscape
The next stop in our around the world in HTAs adventure is Saudi Arabia. This blog breaks down how the Kingdom is reshaping access to new health technologies through regulatory reform, a formal HTA framework, and value-based care. It provides a comprehensive overview of the structural and regulatory reforms underway as part of Vision 2030, highlighting how these changes are reshaping the way new health technologies are evaluated, priced, and brought to market.
The true cost and burden of frontotemporal dementia: Early insights into a pressing challenge
In recognition of Frontotemporal Dementia Awareness Week, OHE shares ongoing work quantifying the disease burden and cost-of-illness associated with FTD.
Latest News
OHE responds to the NHS Ten Year Plan
Professor Graham Cookson responds to the Ten Year Health Plan for England.
OHE statement on 2025 Spending Review
Professor Graham Cookson responds to Chancellor’s Spending Review announcement boosting NHS spend by 3%.
OHE responds to the Trump administration’s Executive Order on Drug Prices
Professor Graham Cookson responds to President Donald Trump’s Executive Order on drug prices published earlier this week.
OHE to host the Health Economists’ Study Group Summer 2025
The Health Economists’ Study Group Summer Meeting will run from 30th June – 2nd July 2025.
OHE’s submission to Belgium’s Committee on Health and Equal Opportunities argues value-based pricing delivers a ‘triple-win’
Professor Cookson argues that value-based pricing would benefit patients and health systems while ensuring ongoing investment in pharmaceutical innovation is incentivised.
New OHE research finds productivity losses from respiratory infections cost UK businesses £44 billion per year
A new report by the Office of Health Economics, funded and commissioned by Pfizer, finds that short-term respiratory infections are an underestimated drain on employees, businesses, and the economy. In particular, presenteeism (working while ill) causes significant productivity losses.
